Tardive dyskinesia (TD): recognition, prevention, and VMAT2 treatment

What TD is and how it develops

TD is a hyperkinetic movement disorder that develops after months to years of exposure to dopamine D2 receptor antagonists. The prevailing mechanism is dopamine receptor supersensitivity: prolonged D2 blockade causes upregulation and increased sensitivity of postsynaptic D2 receptors, which then produce abnormal movements when dopamine reaches them.

Time to onset: typically 6 months to years of exposure. The FDA definition requires at least 3 months of continuous antipsychotic exposure (1 month in patients 60 or older) for a formal diagnosis, but the risk starts accumulating from month one.

Presentation:

• Orofacial dyskinesia (most common): chewing, lip-smacking, tongue protrusion, grimacing, tongue-in-cheek movements
• Limb dyskinesia: choreoathetoid finger movements, foot tapping, toe-curling
• Trunk and neck dyskinesia: swaying, rocking, retrocollis, torticollis
• Respiratory dyskinesia (less common): irregular breathing, grunting

Movements are typically absent during sleep, worsen with stress, and can be temporarily suppressed by voluntary attention. Patients are often unaware of their movements, particularly if cognition is affected.

Distinguishing features:

• TD movements are more choreoform (dance-like, irregular) than tics (repetitive, sudden)
• TD is usually painless (dystonia is often painful)
• TD is usually persistent (drug-induced dystonia often intermittent)
• Onset is delayed after starting the drug (acute EPS occurs early)

The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical assessment. AIMS is quick to perform and should be repeated at baseline and periodically during antipsychotic treatment.

Which drugs cause TD

Highest risk:

• First-generation antipsychotics (haloperidol, fluphenazine, chlorpromazine, perphenazine, trifluoperazine, thiothixene) all carry substantial TD risk, roughly 5 percent per year of exposure
• Metoclopramide (Reglan): substantial TD risk, particularly with prolonged use. FDA black box warning
• Prochlorperazine (Compazine) and promethazine (Phenergan) as antiemetics: real TD risk if used regularly

Moderate risk:

• Second-generation antipsychotics: lower TD risk than first-generation but not zero. Roughly 1 to 3 percent per year in most estimates
• Risperidone and paliperidone have TD signals

Low risk:

• Clozapine: lowest TD risk among antipsychotics. Sometimes used as a TD-sparing alternative in patients who have developed TD
• Quetiapine: low
• Aripiprazole, brexpiprazole, cariprazine (partial agonists): lower than pure antagonists

No TD risk by mechanism:

• Cobenfy (xanomeline-trospium): does not block D2 receptors. Cannot cause TD

Risk factors

Beyond drug and dose, individual factors matter:

• Older age: risk substantially higher after age 60
• Female sex: roughly 1.7 times risk of men in some studies
• Longer treatment duration: cumulative risk increases with time
• Higher cumulative dose: dose-related, though not linear
• Prior EPS or acute dystonia: predictor of later TD
• Cognitive impairment or dementia: elevated risk
• Diabetes: elevated risk
• African American ethnicity: some studies show elevated risk
• Alcohol or substance use disorders: possibly elevated risk

Prevention

TD is easier to prevent than to treat. Two prevention strategies:

Drug selection: For patients with elevated TD risk factors (older adults, women, diabetes, prior EPS), choosing a lower-TD-risk drug is a legitimate first-line decision. Aripiprazole, brexpiprazole, cariprazine, quetiapine, clozapine, lurasidone, lumateperone, and Cobenfy all have lower TD signals than first-generation drugs or risperidone. See the atypical antipsychotics class page.

Lowest effective dose and shortest necessary duration: TD risk is dose- and duration-related. Using the lowest effective antipsychotic dose and reassessing periodically whether continued treatment is required reduces cumulative exposure.

AIMS monitoring at baseline and every 6 to 12 months detects early TD when it may be reversible if the drug is stopped or switched.

Treatment

VMAT2 inhibitors are the first-line pharmacologic treatment:

• Valbenazine (Ingrezza): FDA-approved 2017. Dosing: 40 mg once daily, may increase to 80 mg after 1 week. Once daily oral. Well tolerated. Somnolence is the main dose-limiting side effect.
• Deutetrabenazine (Austedo): FDA-approved 2017. Dosing starts 6 mg twice daily, titrated up to 24 mg twice daily maximum (or 48 mg once daily as Austedo XR). More frequent titration required. Similar efficacy to valbenazine.
• Tetrabenazine (Xenazine): older VMAT2 inhibitor, effective but with more side effects (sedation, depression, akathisia). Rarely first-line now that valbenazine and deutetrabenazine are available.

Drug switch or removal: for patients who can tolerate discontinuation, stopping the causative antipsychotic sometimes reduces TD, though movements often persist and can even worsen initially (withdrawal dyskinesia).

Switch to clozapine: sometimes used for patients with TD who need antipsychotic treatment. Clozapine has the lowest TD risk and can allow gradual improvement over months.

Anticholinergics (benztropine, trihexyphenidyl) are NOT effective for TD and may worsen it. They help acute dystonia but not TD.

Vitamin E, ginkgo biloba, amantadine: mixed evidence, generally less effective than VMAT2 inhibitors.

Common questions

Is tardive dyskinesia permanent? Often yes, but not always. Some patients see improvement or resolution over months to years after stopping the causative drug. Older adults and those with longer exposure are less likely to have full resolution. VMAT2 inhibitors reduce movements but do not cure the underlying supersensitivity.

Which antipsychotic has the lowest TD risk? Clozapine consistently has the lowest TD risk among antipsychotics. Aripiprazole, brexpiprazole, cariprazine, quetiapine, lurasidone, and lumateperone are also low. Cobenfy (xanomeline-trospium) has zero TD risk by mechanism because it does not block D2 receptors. See the Cobenfy state of practice.

Can second-generation antipsychotics cause TD? Yes, though rates are lower than first-generation drugs. Meta-analyses estimate roughly 1 to 3 percent per year for second-generation drugs vs 5 percent per year for first-generation. Risperidone and paliperidone have the highest second-generation TD signals.

How is TD diagnosed? Clinically. AIMS (Abnormal Involuntary Movement Scale) is the standard instrument. There is no lab test or imaging. Diagnosis requires exposure to a dopamine antagonist for at least 3 months (1 month if age 60 or older) and characteristic movements.

Do VMAT2 inhibitors cause depression? Older VMAT2 inhibitors (tetrabenazine) had significant depression and suicidality risk. Newer agents (valbenazine, deutetrabenazine) have much lower rates but the class-wide labeling includes depression as a warning. Baseline mood assessment and periodic monitoring are appropriate.

Can I stop the antipsychotic that caused my TD? Sometimes. If the underlying condition allows drug discontinuation (some patients with brief antipsychotic exposure for a specific reason), stopping is worth considering. For patients with schizophrenia or bipolar disorder who need ongoing antipsychotic treatment, switching to a lower-TD-risk drug is often preferable to stopping entirely. This decision is with the treating clinician.

What about metoclopramide-induced TD? Real and increasingly recognized. Metoclopramide should generally not be used for more than 12 weeks continuously, and should be avoided in older adults where possible. Alternatives for gastroparesis include prucalopride, cisapride (restricted), and dietary/lifestyle management.

Sources

• Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647-656.
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4):463-474.
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD). Lancet Psychiatry. 2017;4(8):595-604.
• American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes. Neurology. 2013;81(5):463-469.
• Bhidayasiri R, Fahn S, Weiner WJ, et al. Practice guideline for the treatment of tardive syndromes. Update summary. Continuum. 2013.